Leerink Partnrs Issues Positive Forecast for REGN Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) – Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Regeneron Pharmaceuticals in a note issued to investors on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings per share of $38.10 for the year, up from their previous estimate of $37.10. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.73 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $7.92 EPS, Q3 2025 earnings at $9.57 EPS and Q4 2025 earnings at $9.27 EPS.

A number of other equities analysts have also commented on REGN. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday. Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Get Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN opened at $683.08 on Wednesday. The company has a market capitalization of $75.06 billion, a PE ratio of 16.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The firm has a 50-day simple moving average of $723.36 and a two-hundred day simple moving average of $928.61. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $666.25 and a 52 week high of $1,211.20.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of REGN. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at about $37,000. Private Wealth Management Group LLC raised its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $39,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.